Long-term Outcome of Irish Wolfhound Dogs with Preclinical Cardiomyopathy, Atrial Fibrillation, or Both Treated with Pimobendan, Benazepril Hydrochloride, or Methyldigoxin Monotherapy
Authors:
Open Access
- 1 March 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 30 (2) , 553-559
Abstract
Background: Dilated cardiomyopathy (DCM) is a common cause of morbidity and mortality in the Irish Wolfhound (IW). However, the benefit of medical treatment in IW dogs with preclinical DCM, atrial fibrillation (AF), or both has not been demonstrated. Objectives: Compare the time to develop congestive heart failure (CHF) or sudden death in IW dogs with preclinical DCM, AF, or both receiving monotherapy with pimobendan, methyldigoxin, or benazepril hydrochloride. Animals: Seventy-five client-owned IW dogs. Methods: Irish Wolfhound dogs were prospectively randomized to receive pimobendan (Vetmedin®)a, benazepril HCl (Fortekor®)b, or methyldigoxin (Lanitop®)c monotherapy in a 1:1:1 ratio in a blinded clinical trial. The prospectively defined composite primary endpoint was onset of CHF or sudden death. To assure stringent evaluation of treatment effect, data from dogs complying with the study protocol were analyzed. Results: Sixty-six IW fulfilling the study protocol included 39 males, 27 females; median (interquartile range) age, 4.0 years (3.0–5.0 years) and weight, 70.0 kg (63.0–75.0 kg). Primary endpoint was reached in 5 of 23 (21.7%) IW receiving pimobendan, 11 of 22 (50.0%) receiving benazepril HCl, and 9 of 21 (42.9%) receiving methyldigoxin. Median time to primary endpoint was significantly longer for pimobendan (1,991 days; 65.4 months) compared to methyldigoxin (1,263 days; 41.5 months; P = .031) or benazepril HCl-(997 days; 32.8 months; P = .008) treated dogs. Conclusions and Clinical Importance: In IW dogs with preclinical DCM, AF or both, pimobendan monotherapy significantly prolonged time to onset of CHF or sudden death than did monotherapy with benazepril HCl or methyldigoxin.Keywords
Funding Information
- Boehringer Ingelheim Vetmedica GmbH
This publication has 35 references indexed in Scilit:
- Efficacy of Pimobendan in the Prevention of Congestive Heart Failure or Sudden Death in Doberman Pinschers with Preclinical Dilated Cardiomyopathy (The PROTECT Study)Journal of Veterinary Internal Medicine, 2012
- Adverse Bioenergetic Consequences of Na + -Ca 2+ Exchanger–Mediated Ca 2+ Influx in Cardiac MyocytesCirculation, 2010
- Efficacy of Benazepril Hydrochloride to Delay the Progression of Occult Dilated Cardiomyopathy in Doberman PinschersJournal of Veterinary Internal Medicine, 2009
- Effectiveness of Digoxin in Reducing One-Year Mortality in Chronic Heart Failure in the Digitalis Investigation Group TrialThe American Journal of Cardiology, 2009
- Effect of Pimobendan on Case Fatality Rate in Doberman Pinschers with Congestive Heart Failure Caused by Dilated CardiomyopathyJournal of Veterinary Internal Medicine, 2008
- A Double-Blind, Randomized, Placebo-Controlled Study of Pimobendan in Dogs with Dilated CardiomyopathyJournal of Veterinary Internal Medicine, 2002
- Preferences of veterinarians for drugs to treat heart disease in dogs and catsAustralian Veterinary Journal, 1995
- Activation of the renin-angiotensin system in dogs with asymptomatic and symptomatic dilated cardiomyopathyResearch in Veterinary Science, 1995
- Recommendations for Standards in Transthoracic Two-Dimensional Echocardiography in the Dog and CatJournal of Veterinary Internal Medicine, 1993
- An electrocardiographic survey of cardiac rhythm in Irish wolfhoundsVeterinary Record, 1991